

EDITORIAL

PHARMA, PHYSICIAN NEXUS -A PERIL IN THE OFFING

Abdul Wahab Yousafzai¹, Fatimah Saeed²

Department of Psychiatry, Shifa International Hospital, Islamabad-Pakistan

Pharmaceutical companies and healthcare professionals have long been a subject of scrutiny, as their collaboration plays a pivotal role in advancing medical research, promoting evidence-based practices, and fostering dialogue among healthcare practitioners. Together, they have pushed the boundaries of scientific innovation, paving the way for groundbreaking medical advancements. However, ethical concerns arise when such collaborations cross the line into lavish sponsorships for physicians, including all-expenses-paid trips to international conferences and seminars. The opaque ties between the pharmaceutical industry and Physicians cast a shadow on the sanctity of impartial medical practice, particularly in a nation like Pakistan where regulatory frameworks are a work in progress. While the undeniable benefits of collaboration between pharmaceutical companies and medical practitioners are evident, it is imperative to address the ethical implications when such partnerships tread perilously close to the line between ethical collaboration and ethically questionable practices.

Keywords: Pharmaceutical Collaboration; Healthcare; Ethics; Sponsorship; Pakistan

Citation: Yousafzai AW, Saeed F. Pharma, Physician nexus -A peril in the offing. J Ayub Med Coll Abbottabad 2023;35(4):521-2.

DOI: 10.55519/JAMC-04-12530

The ethical quandary is most pronounced when physicians prioritise personal gain or corporate interests over patient welfare, it jeopardises the quality of clinical care. Patient trust may erode, leading to the deterioration of the doctor-patient relationship.¹ The overemphasis on sponsored trips and perks can divert medical professionals' focus from their primary responsibility; promoting evidence-based practices and delivering optimal patient care.²

In a global corruption index comparing 182 countries, Pakistan's ranking stands at 134th place. Unfortunately, this issue extends to the healthcare sector as well, where a lack of accountability, lax regulations, and inadequate documentation systems prevail.³ In the year 2023, Pakistan witnessed the participation of hundreds of its Physicians in several International Psychiatry conferences held overseas (Personal Communication). These gatherings, although enriching the knowledge base of Pakistani medical professionals, raised significant questions about the ethical implications surrounding the nexus between pharmaceutical companies and medical practitioners in a country where regulatory oversight remains relatively weak.⁴

Collaborations between pharmaceutical companies and healthcare practitioners undoubtedly hold potential benefits for advancing medical progress. However, they introduce a complex issue of potential conflicts of interest, which can manifest as undue influence and compromise the quality of patient care.⁵ To uphold the integrity of medical practice, it is imperative that physicians, healthcare institutions, and

regulatory bodies establish and adhere to stringent ethical guidelines that consistently prioritise patient well-being over personal gain or corporate interests.⁶

Sponsorships can set a problematic precedent, particularly for students, trainees, and junior doctors who might perceive these trips as a marker of success. This can lead to a skewed value system, emphasising material benefits over genuine patient welfare. The next generation of healthcare professionals should learn that their primary responsibility is the wellness of their patients.⁷

The most pressing ethical issue is the potential for conflicts of interest. When pharmaceutical companies foot the bill for trips, there's a risk that physicians might be influenced in their prescribing habits, favouring medications from the sponsoring company over potentially more effective or cost-efficient alternatives.^{8,9} Medical experts are meant to offer unbiased and evidence-based care to their patients. However, sponsorships can compromise this objectivity, as doctors may feel indebted to the companies that have funded their trips, impacting their ability to provide impartial medical advice.¹⁰ By focusing on sponsoring specific physicians or specialties, pharmaceutical companies may inadvertently steer medical perspectives towards their own products, neglecting other equally valid treatment options.¹¹

Therefore, the call for ethical clarity within healthcare collaborations becomes more urgent when considering the ripple effects on future clinicians.¹² The educational journey of students, trainees, and

aspiring healthcare practitioners extends beyond the acquisition of medical knowledge; and incorporation of a value system that strongly focuses on patient prosperity. The troubling reality arises when these aspirants witness established professionals prioritising personal gain over the sanctity of patient care. This not only perpetuates a skewed value system but also has the potential to erode the essence of medical care, the absolute commitment to patient welfare.¹³

By establishing and upholding rigorous ethical guidelines, we not only protect the sanctity of patient care but also lay a foundation for the healthcare community that prioritises principles over perks.^{14,15}

Striving for this higher standard is not only a moral imperative but also a strategic move that strengthens the resilience of the healthcare field against ethical dilemmas and misguided priorities. Medical professionals must recognize the importance of role-modelling ethical behaviour for students and trainees. Serving as ethical compasses in medical practice sets a powerful example for the next generation, reinforcing the values of patient-centred care within the community. The inclusion of behavioural science at the undergraduate level in medical college, with a special emphasis on teaching medical ethics and fostering evidence-based and patient-centred practice, is a pivotal step toward nurturing well-rounded, ethically aware, and patient-centric healthcare professionals. By implementing a comprehensive curriculum that amalgamates behavioural science, medical ethics, and the ingrained practice of evidence-based methodologies, prospective clinicians will be aptly equipped to manoeuvre the intricate terrain of healthcare collaborations while steadfastly upholding the paramount concern for the welfare of their patients.

REFERENCES

1. Nie J, Yu C, Zou X, Gong N, Tucker JD, Wong BC, *et al.* The vicious circle of patient-physician mistrust in China: health professionals' perspectives, institutional conflict of interest, and building trust through medical professionalism. *Dev World Bioeth* 2018;18(1):26–36.
2. Smith, R. Beyond conflict of interest. *BMJ* 1998;317(7154):291–2.
3. Yousafzai AW. Corruption in medical practice: Where do we stand? *J Ayub Med Coll Abbottabad* 2015;27(3):515–6.
4. De Andrade M, Jafarey A, Shekhani SS, Angelova N. The ethics of pharma-physician relations in Pakistan: "When in Rome." *Ethics Behav* 2019;29(6):473–89.
5. Lo B, Field MJ. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice. *Conflict of Interest in Medical Research, Education, and Practice*. Washington (DC): National Academies Press (US); 2009.
6. Adane K, Worku L, Deress T, Tesfahun A. Ethical practice in medicine: a review [Internet]. In Review; 2020 Jan [cited 2023 Oct 11]. Available from: <https://www.researchsquare.com/article/rs-12820/v1>
7. Vassilas CA, Matthews S. Pharmaceutical sponsorship of educational events: what can we learn from healthcare ethics? *Psychiatr Bull* 2006;30(5):189–91.
8. Ohta R, Sano C. Overcoming ethical issues surrounding the relationships between physicians and pharmaceutical companies in rural hospitals. *Cureus* 2023;15(8):e43320.
9. Thompson DF. Understanding financial conflicts of interest. *N Engl J Med* 1993;329(8):573–6.
10. Nelson B. A trip to remember, with strings attached: Researchers begin sorting through the tangled ethical and legal implications of medical tourism. *Cancer Cytopathol* 2014;122(11):787–8.
11. Lexchin J. Sponsorship bias in clinical research. *Int J Risk Saf Med* 2012;24(4):233–42.
12. Komesaroff PA. Ethical issues in the relationships involving medicine and industry: evolving problems require evolving. *Intern Med J* 2005;35(4):203–5.
13. Hofman PB. Upholding patient rights through ethical policymaking. *Trustee* 1985;38(4):15–6.
14. Thompson I. Fundamental ethical principles in health care. *BMJ* 1987;295(6611):1461–5.
15. Murray JS. Moral Courage in Healthcare: Acting Ethically Even in the Presence of Risk. *Online J Issues Nurs*. 2010;15(3):1–3.

Address for Correspondence:

Abdul Wahab Yousafzai, Head of Psychiatry Department, Shifa International Hospital, Islamabad-Pakistan.

Cell: +92 321 221 7918

Email: wahab.yousafzai@gmail.com